ImageneBio (IMA) Short term Debt (2024)
ImageneBio (IMA) posted Short term Debt of $7.5 million for Q4 2024.
ImageneBio (IMA) Short term Debt (2024) Analysis & Trends
ImageneBio has reported Short term Debt for 1 years, with the latest figure at $7.5 million in Q4 2024.
- Quarterly Short term Debt changed N/A year-over-year to $7.5 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $7.5 million (changed N/A YoY) and the FY2024 annual result came in at $7.5 million, changed N/A from the prior year.
- Short term Debt was little changed at $7.5 million in Q4 2024 per IMA's latest filing.
- Over five years, Short term Debt peaked at $7.5 million in Q4 2024 and troughed at $7.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - |
| 10 | ImageneBio | 47.79 Mn | -87.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 7.50 Mn |